Bictegravir
- CAS No.
- 1611493-60-7
- Chemical Name:
- Bictegravir
- Synonyms
- BICTEGRAVIR-D5;GS-9883;Bitravir;GS-9883-01;Bictegravin;Bictegravir;BNKY010-BC03;Bictegravir (GS-9883);Bictegravir, 10 mM in DMSO;Bictegravir (100 mg/mL in DMSO)
- CBNumber:
- CB63161551
- Molecular Formula:
- C21H18F3N3O5
- Molecular Weight:
- 449.38
- MDL Number:
- MFCD31536971
- MOL File:
- 1611493-60-7.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Product description | Number | Pack Size | Price |
| Bictegravir ≥98% | 26532 | 250mg | $50 |
| Bictegravir ≥98% | 26532 | 500mg | $95 |
| Bictegravir ≥98% | 26532 | 1g | $129 |
| Bictegravir | 26532 | 1mg | $26 |
| Bictegravir | 26532 | 10mg | $796 |
| More product size | |||
| Melting point | >130°C (dec.) |
|---|---|
| Boiling point | 682.5±55.0 °C(Predicted) |
| Density | 1.62±0.1 g/cm3(Predicted) |
| storage temp. | Sealed in dry,Store in freezer, under -20°C |
| solubility | DMSO (Slightly), Methanol (Slightly) |
| pka | 4.50±1.00(Predicted) |
| form | Solid |
| color | White to Off-White |
| InChIKey | SOLUWJRYJLAZCX-LYOVBCGYSA-N |
| SMILES | O1[C@@]2([H])C[C@]([H])(CC2)N2C(=O)C3=C(O)C(=O)C(C(NCC4=C(F)C=C(F)C=C4F)=O)=CN3C[C@@]12[H] |
| FDA UNII | 8GB79LOJ07 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H315-H319-H335 | |||||||||
| Precautionary statements | P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P321-P362+P364-P332+P313-P337+P313-P403+P233-P405-P501 | |||||||||
| NFPA 704 |
|
Bictegravir price More Price(64)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 26532 | Bictegravir ≥98% | 1611493-60-7 | 250mg | $50 | 2026-04-30 | Buy |
| Cayman Chemical | 26532 | Bictegravir ≥98% | 1611493-60-7 | 500mg | $95 | 2026-04-30 | Buy |
| Cayman Chemical | 26532 | Bictegravir ≥98% | 1611493-60-7 | 1g | $129 | 2026-04-30 | Buy |
| Cayman Chemical | 26532 | Bictegravir | 1611493-60-7 | 1mg | $26 | 2024-03-01 | Buy |
| Cayman Chemical | 26532 | Bictegravir | 1611493-60-7 | 10mg | $796 | 2023-06-20 | Buy |
Bictegravir Chemical Properties,Uses,Production
Synthesis
Step 1: 1-(2,2-dimethoxyethyl)-5-methoxy-6-(methoxycarbonyl)-4-oxo-1,4-dihydropyridine-3-carboxylic acid (1-A, 3.15 g, 10.0 mmol) suspended in acetonitrile (36 mL) and acetic acid (4 mL) was treated with methanesulfonic acid (0.195 mL). The mixture was heated to 75 °C. After 7 hours, the crude mixture was cooled and stored at -10 °C for three days. The crude mixture was reheated to 75 °C for 2 hours, cooled, and used in the next step without purification.
Step 2: Crude 1-(2,2-dihydroxyethyl)-5-methoxy-6-(methoxycarbonyl)-4-oxo-1,4-dihydropyridine-3-carboxylic acid (16.8 mL from the crude mixture of Step 1, approximately 4 mmol) was mixed with (1S,3R)-3-aminocyclopentanol (0.809 g, 8 mmol), diluted with acetonitrile (16.8 mL), and treated with potassium carbonate (0.553 g, 4 mmol). The reaction mixture was heated to 85 °C, stirred for 15 min, cooled to ambient temperature, and stirred again for 16 h. HCl (50 mL, 0.2 Maq) was added, and the clear yellow solution was extracted three times with dichloromethane. The combined organic layers were dried over sodium sulfate, filtered, and concentrated to a yellow solid. The crude substance was precipitated from dichloromethane/hexane to give the desired intermediate 15-B as a light beige powder. Step 3: Compound 15-B (38 mg, 0.12 mmol) was dissolved in 1 mL of acetonitrile and treated with 2,4,6-trifluorobenzylmethylamine (34 mg, 0.21 mmol), HATU (50 mg, 0.13 mmol), and N,N-diisopropylethylamine (DIPEA) (23 mg, 0.18 mmol) and stirred at room temperature for 2 hours. Subsequent LCMS analysis showed that compound 15-B was completely consumed and intermediate 45-A was formed. The reaction mixture was then proceeded to the next step. Step 4: MgBr2 (55 mg, 0.30 mmol) was added to the crude reaction solution from the previous step. The reaction mixture was stirred at 50 °C for 1 hour, acidified with 10% HCl aqueous solution, partitioned between aqueous solution and dichloromethane, and the aqueous phase was extracted with dichloromethane. The combined organic phases were dried over MgSO4, filtered, concentrated, and purified by HPLC (ACN/H2O containing 0.1% TFA modifier) to obtain compound 45-Bictegravir.Description
Bictegravir (BIC) is a second-generation integrase strand transfer inhibitor (InSTI), like dolutegravir, with higher genetic barrier to resistance than raltegravir and elvitegravir.
Bictegravir is a human immunodeficiency virus (HIV) integrase strand transfer inhibitor, the fourth in this class of agents that target the viral integrase. Bictegravir is used only in combination with other antiretroviral agents in the treatment of HIV infection and it has had limited use. Bictegravir is associated with a low rate of serum aminotransferase elevations during therapy, but has not been linked to instances of acute, clinically apparent liver injury.
Uses
Bictegravir, is a novel, potent inhibitor of HIV-1 integrase with an IC50 of 7.5 nM.
Application
Bictegravir, is a novel, potent inhibitor of HIV-1 integrase with an IC50 of 7.5 nM. Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet. Bictegravir is indicated in the management of HIV-1 infection in patients not previously treated with antiretroviral therapy. Additionally, Bictegravir is indicated in the management of HIV-1 infection in patients who are virologically suppressed (HIV-1 RNA <50 c/mL) on a regular antiretroviral regimen for a minimum of three months without a history of failure in treatment and no known factors associated with the resistance to the individual components of the medication. It is used in combination with tenofovir and emtricitabine.
Definition
ChEBI: Bictegravir is a monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxylic acid with the amino group of 2,4,6-trifluorobenzylamine. It is a second-generation integrase strand transfer inhibitor (INSTI) and used (as its sodium salt) for the treatment of HIV-1. It has a role as a HIV-1 integrase inhibitor. It is a monocarboxylic acid amide, a secondary carboxamide, a trifluorobenzene and an organic heterotetracyclic compound. It is a conjugate acid of a bictegravir(1-).
Mechanism of action
This single dose medication inhibits the strand transfer of viral DNA into the human genome, preventing HIV-1 virus replication and propagation 2.
In vitro, bictegravir has shown powerful antiviral activity against HIV-2 and various subtypes of HIV-1. It has shown synergistic effects when combined with other ARVs, including tenofovir alafenamide (TAF), emtricitabine (FTC), and darunavir (DRV) Label. The three components of the first USA approved medication ( trade name: Biktarvy ) are as follows:
Bictegravir: integrase strand transfer inhibitor; INSTI), an HIV-1 encoded enzyme necessary for viral replication. Inhibition of the integrase enzyme prevents the integration of HIV-1 into host DNA, blocking the conversion of the HIV-1 provirus and progression of the virus.
Emtricitabine: FTC, is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate. Emtricitabine is phosphorylated to form emtricitabine 5'-triphosphate intracellularly. This metabolite inhibits the activity of human immunodeficiency virus (HIV) reverse transcriptase by competing with the substrate deoxycytidine 5'-triphosphate and by incorporating itself into viral DNA preventing DNA chain elongation.
Tenofovir Alafenamide: TAF is a phosphonamidate prodrug of tenofovir (2′-deoxyadenosine monophosphate analog). Plasma exposure to TAF leads to leakage into cells and then TAF is intracellularly converted to tenofovir by hydrolysis by cathepsin. Tenofovir is subsequently phosphorylated by cellular kinases to the metabolite tenofovir diphosphate, which is the active form of the drug. Tenofovir diphosphate inhibits HIV-1 replication by incorporating into viral DNA by the HIV reverse transcriptase, resulting in DNA chain-termination. Tenofovir diphosphate also weakly inhibits mammalian DNA polymerases.
Pharmacokinetics
Bictegravir is an HIV-1 integrase strand transfer inhibitor (INSTI). Bictegravir (BIC) inhibits HIV-1 virus replication into the human genome. It can be taken once daily without additional dosing. Bictegravir (BIC) inhibits strand transfer of viral DNA into the host genome and thereby prevents HIV-1 replication.
Side effects
Allergic reactions—skin rash, itching, hives, swelling of the face, lips, tongue, or throat;
High lactic acid level—muscle pain or cramps, stomach pain, trouble breathing, general discomfort and fatigue;
Infection—fever, chills, cough, or sore throat;
Kidney injury—decrease in the amount of urine, swelling of the ankles, hands, or feet;
Liver injury—right upper belly pain, loss of appetite, nausea, light-colored stool, dark yellow or brown urine, yellowing skin or eyes, unusual weakness or fatigue;
Diarrhea, Headache, Nausea
Bictegravir Preparation Products And Raw materials
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| shandong perfect biotechnology co.ltd | +86-53169958659 +86-13153181156 | sales@sdperfect.com | China | 293 | 58 |
| Hangzhou ICH Biofarm Co., Ltd | +86-0571-28186870; +undefined8613073685410 | sales@ichemie.com | China | 1002 | 58 |
| Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 | info@tianfuchem.com | China | 21533 | 55 |
| career henan chemical co | +86-0371-86658258 | sales@coreychem.com | China | 29766 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32431 | 58 |
| Hefei Hangang Pharmaceutical Technology Co., Ltd. | +8618062405514 | ada@ipurechemical.com | China | 10224 | 58 |
| Changzhou Xuanming Pharmaceutical Technology Co., Ltd. | +86-519-85525359 +86-15995072465 | sales@xuanmingchem.com | China | 912 | 58 |
| Dideu Industries Group Limited | +8617392712697 | 1022@dideu.com | China | 29091 | 58 |
| AFINE CHEMICALS LIMITED | +86-571-85134551 +86-18958018566 | info@afinechem.com | China | 15031 | 58 |
| Wuhan Fortuna Chemical Co., Ltd | +86-27-59207850 | info@fortunachem.com | China | 5986 | 58 |
Related articles
- The application of bictegravir, emtricitabine, and tenofovir alafenamide.
- The combination of bictegravir, emtricitabine, and tenofovir AF is used to treat human immunodeficiency virus (HIV) infection ....
- Mar 19,2024
- Bictegravir: a novel integrase strand transfer inhibitor
- Bictegravir is a novel integrase strand transfer inhibitor (INSTI) developed by Gilead Sciences as a treatment for HIV-1 infec....
- Dec 20,2023
View Lastest Price from Bictegravir manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-09-04 | Bictegravir
1611493-60-7
|
10g | 98%min | 10kgs | WUHAN FORTUNA CHEMICAL CO., LTD | ||
 |
2026-08-20 | Bictegravir
1611493-60-7
|
$1.10 | 1g | 99.0% Min | 100 Tons | Dideu Industries Group Limited | |
 |
2026-08-08 | Bictegravir
1611493-60-7
|
1kg | 99.0% | 20 tons | Hangzhou ICH Biofarm Co., Ltd |
-
- Bictegravir
1611493-60-7
- 98%min
- WUHAN FORTUNA CHEMICAL CO., LTD
-
- Bictegravir
1611493-60-7
- $1.10
- 99.0% Min
- Dideu Industries Group Limited
-
- Bictegravir
1611493-60-7
- 99.0%
- Hangzhou ICH Biofarm Co., Ltd
1611493-60-7(Bictegravir)Related Search:
1of4
